Global Therapeutic Proteins Market Predicted to Grow at 13.5% CAGR During 2026-2030
The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.
What Is the Forecast Market Size and Growth Rate of the Therapeutic Proteins Market?
The therapeutic proteins market size has grown rapidly in recent years. It will grow from $177.3 billion in 2025 to $200.43 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to successful commercialization of insulin therapies, rising prevalence of chronic diseases, strong clinical efficacy of protein drugs, growth of biotechnology research, increased regulatory approvals.
The therapeutic proteins market size is expected to see rapid growth in the next few years. It will grow to $332.37 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to expanding oncology and immunology pipelines, increasing biologics approvals, rising investment in biopharmaceutical R&D, growing adoption of biosimilars, improved manufacturing scalability. Major trends in the forecast period include expansion of recombinant protein therapies, rising demand for targeted biologics, growth of personalized protein medicines, increased adoption of long acting proteins, advancement in protein expression systems.
Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report
What Are the Key Factors Contributing to Therapeutic Proteins Market Growth?
The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesized chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic proteins drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic proteins drugs developed using protein engineering technologies and approved by the FDA in the past five years.
What Are the Main Segments of the Therapeutic Proteins Market?
The therapeutic proteins market covered in this report is segmented –
1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone
2) By Function: Enzymatic And Regulatory Activity, Special Targeting Activity, Vaccines
3) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications
Subsegments:
1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin
2) By Fusion Protein: Tnf-Alpha Inhibitors, Anti-Cd20 Fusion Proteins, Other Targeted Fusion Proteins
3) By Erythropoietin: Epoetin Alpha, Darbepoetin Alfa, Other Erythropoietin Variants
4) By Interferon: Interferon Alpha, Interferon Beta, Interferon Gamma
5) By Human Growth Hormone: Somatropin, Somatrem
6) By Follicle Stimulating Hormone: Follitropin Alpha, Follitropin Beta
What Are the Future Trends Forecasted for the Therapeutic Proteins Market?
Major companies operating in the therapeutic protein market are focused on introducing media systems to meet growing demand for therapeutic proteins and gain a competitive edge in the market. The media system for therapeutic proteins is a production system designed to optimize the production of therapeutic monoclonal antibodies. For instance, in July 2023, Lonza Group AG, a Switzerland-based pharmaceutical manufacturing company, launched the TheraPRO CHO (Chinese Hamster Ovary) Media System, a new cell culture platform to improve productivity and quality in therapeutic protein manufacture. The two-part, chemically specified production technique is simple to use and makes media preparation easier. It has full scalability and is supported by technical professionals with in-depth troubleshooting knowledge.
Who Are the Industry Leaders in the Therapeutic Proteins Market?
Major companies operating in the therapeutic proteins market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A, Bristol Myers Squibb Co., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring LLC, Chugai Pharmaceutical Co. Ltd., Biogen Inc., Kyowa Kirin Co. Ltd., Oramed Pharmaceuticals Inc., Sandoz International GmbH, Hualan Biological Engineering Inc., Genentech Inc., ProBiogen AG, Diasome Pharmaceuticals Inc., Generex Biotechnology Corp., GeneScience Pharmaceuticals Co. Ltd.
Get the full therapeutic proteins market report here:
https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report
Which region represents the fastest-growing market for the Therapeutic Proteins Market?
North America was the largest region in the therapeutic proteins market in 2025. The regions covered in the therapeutic proteins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment